CTSO - cytosorbents.com Debt to Book Capitalization Ratio

Corporate company logo of CytoSorbents Corp. (CTSO)

The debt-to-market capitalization ratio generated by GURU.Markets quotes currently holds the status of 0.00. This price action confirms the leadership of Cytosorbents (CTSO) in the sorption systems niche, which allows the company to avoid dumping. Revenues are based on the supply of disposable cartridges to surgical centers for the treatment of sepsis. Stable demand is ensured through physician training, transforming consumables into a reliable cash cow.

CytoSorbents Corp - CTSO Debts to Book Capitalization (period 07/04/2022 - 10/27/2026)
Flagship merchandise of CytoSorbents Corp

This indicator reflects the proportion of borrowed funds relative to the company's equity. Analyzing this ratio allows an investor to assess financial stability and the risk of excessive debt load. The trend on the total debt-to-equity chart helps identify dangerous asset overvaluation in a timely manner. For Cytosorbents (CTSO), this balance is critical when financing expansion into the US market. Debt optimization will secure the resources necessary for the certification of new blood purification systems.

Competitors of Cytosorbents

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|TCMD - Debt to Book Capital|SANUWAVE - Debts to Book Capitalization|Outset Medical Inc (OM) - Debts to Net Assets|Debts to Book Capitalization ELMD|Debt to Book Value LENSAR Inc (LNSR)|AVITA Medical, Inc. (RCEL) - Debt to Book Value|Debt to Net Assets Ratio PROF (profoundmedical.com)|Baird Medical - Debt to Book Capitalization Ratio|Debt to Book Value EDAP TMS SA EDAP|APYX (Bovie Medical) - Debts to Book Capitalization|ICCM - Debts to Book Value|Debts to Book Capitalization pulmonx.com|TELA Bio (TELA) - Debt to Book Value Ratio|SRTS: Debts to Book Capitalization|Debts to Net Assets Zynex Medical|Debts to Book Capitalization ECOR (electroCore, Inc.)|Debt to Book Value vicarioussurgical.com (RBOT)|Debts to Book Capitalization IINN (Inspira Technologies)|seastarmedical.com - Debts to Book Capitalization|IRIX - Debt to Book Capitalization Ratio|Intelligent Bio Solutions (INBS) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio